Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 5, 2017, Pages 1400-1409

  Buyck, J M ^a,d   Luyckx, C ^a   Muccioli, G G ^a   Krause, K M ^b,e   Nichols, W W ^c   Tulkens, P M ^a   Van Bambeke, F ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Cerexa Inc   (United States)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITÉ DE POITIERS   (France)

^e Achaogen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; BETA LACTAMASE AMPC; CEFTAZIDIME; COLISTIN; GENTAMICIN; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR BACTERIUM; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; PHAGOCYTOSIS; PHARMACODYNAMICS; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REVERTANT; CYTOPLASM; DRUG EFFECTS; GENETICS; KINETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MONONUCLEAR CELL; TANDEM MASS SPECTROMETRY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; CYTOPLASM; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; TANDEM MASS SPECTROMETRY;

EID: 85020086122     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw587     Document Type: Article

References (41)

1. Ruppé E, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care 2015; 5: 61
2. Buyck JM, Lemaire S, Seral C et al. In vitro models for the study of the intracellular activity of antibiotics. MethodsMol Biol 2016; 1333: 147-57
3. Bonnefoy A, Dupuis-Hamelin C, Steier V et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam b-lactamase inhibitor. JAntimicrobChemother 2004; 54: 410-7
4. Robbins MJ, Cassettari M, Dencer C et al. In vitro activity of NXL104 (NXL), a newb-lactamase inhibitor, in combinationwith cefpodoxime (CPD) and cefixime (CFM) against 3rd generation cephalosporin-resistant isolates of species of the Enterobacteriaceae. In: Abstracts of the Forty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 Abstract F-1161, p. 187. American Society for Microbiology, Washington, DC, USA
5. Livermore DM, Mushtaq S, Warner M et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum b-lactamases and carbapenemases. JAntimicrobChemother 2008; 62: 1053-6
6. Wang DY, Abboud MI, Markoulides MS et al. The road to avibactam: the first clinically useful non-β-lactamworking somewhat like a b-lactam. Future Med Chem 2016; 8: 1063-84
7. Bush K. A resurgence of b-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 2015; 46: 483-93
8. Zhanel GG, Lawson CD, AdamH et al. Ceftazidime-avibactam: a novel cephalosporin/b-lactamase inhibitor combination. Drugs 2013; 73: 159-77
9. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime! NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 2010; 65: 2376-81
10. Lahiri SD, Johnstone MR, Ross PL et al. Avibactam and class C b-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother 2014; 58: 5704-13
11. Flamm RK, Stone GG, Sader HS et al. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-offvalue. JChemother 2014; 26: 333-8
12. Sader HS, Castanheira M, Flamm RK et al. Antimicrobial activity of ceftazidime-avibactamagainst Gram-negative organisms collected fromU. S. medical centers in 2012. Antimicrob Agents Chemother 2014; 58: 1684-92
13. NicholsWW, de Jonge BLM, Kazmierczak KMet al. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidimeavibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 2016; 60: 4743-9
14. US FDA, Silver Spring, MD, USA. Avycaz Prescribing Information. http://www. accessdata. fda. gov/drugsatfda_docs/label/2015/206494lbl. pdf
15. EMA, London, UK. Zavicefta Summary of Product Characteristics. http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Product_Inform ation/human/004027/WC500210234. pdf
16. Buyck JM, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in amodel of THP-1 human monocytes. Antimicrob Agents Chemother 2013; 57: 2310-8
17. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 1177-84
18. Livermore DM, Yang YJ. b-Lactamase lability and inducer power of newer b-lactam antibiotics in relation to their activity against b-lactamaseinducibility mutants of Pseudomonas aeruginosa. J Infect Dis 1987; 155: 775-82
19. Livermore DM. Interplay of impermeability and chromosomal b-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 2046-8
20. Riou M, Carbonnelle S, Avrain L et al. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of intensive care unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents 2010; 36: 513-22
21. Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014
22. Bogaerts P, Rezende de Castro R, de Mendonca R et al. Validation of carbapenemase and extended-spectrum b-lactamase multiplex endpoint PCR assays according to ISO15189. J Antimicrob Chemother 2013; 68: 1576-82
23. Tulkens P, Trouet A. The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts. Biochem Pharmacol 1978; 27: 415-24
24. Steinman RM, Brodie SE, Cohn ZA. Membrane flow during pinocytosis. A stereologic analysis. J Cell Biol 1976; 68: 665-87
25. Melard A, Garcia LG, Das D et al. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin. J Antimicrob Chemother 2013; 68: 648-58
26. de Duve C, de Barsy T, Poole B et al. Commentary. Lysosomotropic agents. BiochemPharmacol 1974; 23: 2495-531
27. Lemaire S, Glupczynski Y, Duval V et al. Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 2289-97. PM:19289525
28. Peyrusson F, Butler D, Tulkens PM et al. Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murinemacrophages. Antimicrob Agents Chemother 2015; 59: 5747-60
29. Van Bambeke F, Tulkens PM, Limited maximal activity without marked loss of potency of antibiotics against intracellular forms of Staphylococcus aureus and Pseudomonas aeruginosa: an analysis with 13 bactericidal antibiotics from 7 different pharmacological classes in a pharmacodynamicmodel of human THP-1 infected monocytes. Poster Saturday-571. In: Abstracts of ASMMicrobe 2016, Boston, MA, USA, 2016. American Society forMicrobiology, Washington DC, USA
30. Van Bambeke F, Barcia-Macay M, Lemaire S et al. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr Opin Drug Discov Dev 2006; 9: 218-30
31. Shigeoka AO, Hill HR. Recurrent Pseudomonas infection associated with neutrophil dysfunction. Scand J Infect Dis 1978; 10: 307-11
32. Bayston R, Andrews M, Rigg K et al. Recurrent infection and catheter loss in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1999; 19: 550-5
33. Drilling A, Coombs GW, Tan H et al. Cousins, siblings, or copies: the genomics of recurrent Staphylococcus aureus infections in chronic rhinosinusitis. Int Forum Allergy Rhinol 2014; 4: 953-60
34. Hamza T, Dietz M, Pham D et al. Intra-cellular Staphylococcus aureus alone causes infection in vivo. Eur CellMater 2013; 25: 341-50
35. Schmiedl A, Kerber-Momot T, Munder A et al. Bacterial distribution in lung parenchyma early after pulmonary infection with Pseudomonas aeruginosa. Cell Tissue Res 2010; 342: 67-73
36. Takajo D, Iwaya K, Katsurada Y et al. Community-acquired lobar pneumonia caused by Pseudomonas aeruginosa infection in Japan: a case report with histological and immunohistochemical examination. Pathol Int 2014; 64: 224-30
37. McClure CD, Schiller NL. Inhibition of macrophage phagocytosis by Pseudomonas aeruginosa rhamnolipids in vitro and in vivo. Curr Microbiol 1996; 33: 109-17
38. Nakao M, Kondo M, Imada A et al. An electron microscopic study of pathogenesis of urinary tract infection caused by Pseudomonas aeruginosa P. 9 inmice. Zentralbl Bakteriol Mikrobiol Hyg A 1985; 260: 369-78
39. Carryn S, Van de Velde S, Van Bambeke F et al. Impairment of growth of Listeria monocytogenes in THP-1 macrophages by granulocyte macrophage colony-stimulating factor: release of tumor necrosis factor-a and nitric oxide. J Infect Dis 2004; 189: 2101-9
40. Berkhout J, Melchers MJ, van Mil AC et al. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother 2016; 60: 368-75
41. Sy SKB, Beaudoin ME, Zhuang L et al. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. J Antimicrob Chemother 2016; 71: 1866-80